Back to results

Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer (WFPBD)

Primary Purpose

Prostate Cancer

Status

Recruiting

Phase

Not Applicable

Locations

United States

Study Type

Interventional

Intervention

Whole-food, Plant-Based Diet

General Nutritional Counseling

About this trial

This is an interventional treatment trial for Prostate Cancer

Eligibility Criteria

45 Years - 99 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria

Histologically or cytologically confirmed adenocarcinoma of the prostate
Receiving androgen deprivation therapy (ADT) with an LHRH/GnRH analogue (agonist/antagonist); or have undergone bilateral orchiectomy. Patients with localized prostate cancer, non-metastatic castrate resistant prostate cancer (CRPC), metastatic hormone sensitive prostate cancer and metastatic CRPC are all eligible.
On ADT for at least 24 weeks pre-study with anticipation of at least 26 more weeks of therapy from the date of initiation of the dietary intervention
Patients receiving an anti-androgen (including, but not limited to drugs such as bicalutamide, abiraterone, enzalutamide or apalutamide) are eligible if they have been on therapy for at least 3 months and plan to continue for the duration of the study
At least 3 months post completion of chemotherapy and/or radiation
Bone resorptive agents such as bisphosphanates and denosumab are allowed.
Testosterone level <50 ng/dL
Age ≥ 45 years
BMI ≥ 27
ECOG performance status of 0 to 1
Adequate organ and marrow function, based upon meeting all of the following laboratory criteria:
1. White blood cell count ≥ 2500/mm3 (≥ 2.5 GI/L)
2. Platelets ≥ 100,000/mm3 (≥ 100 GI/L) without transfusion
3. Hemoglobin ≥ 9 g/dL (≥ 90 g/L)
4. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin ≤ 2x ULN (or for subjects with Gilbert's disease direct bilirubin WNL)
5. Serum albumin ≥ 2.8 g/dl
Willingness and ability to comply with all study-related procedures
Capable of understanding and complying with the protocol requirements and must have signed the informed consent document

Exclusion Criteria

Insulin-dependent diabetes mellitus
Nut or legume allergy, gluten intolerance or celiac disease
Currently consuming a vegetarian or vegan diet
Concurrent participation in other nutrition or weight loss programs
Expected changes in chronic medications, including statins or oral diabetes medication during the study period (including a change in medication dosage)
Expected radiation, chemotherapy, bone resorptive agents or anti-androgen within 2 months of beginning the diet intervention
Expected changes in exercise patterns during the study period
Psychiatric illnesses or social situations that would limit compliance with study requirements, including a living situation that does not allow for the delivery of Plantable prepared meals, or the inability or lack of equipment to perform basic cooking tasks
Known history of electrolyte imbalance or micronutrient deficiency, e.g., magnesium, cobalamin
Ongoing use of warfarin anticoagulants
Diagnosed, active inflammatory bowel disease
Inability to receive Emails or have a smart phone

Sites / Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer CenterRecruiting
Weill Cornell MedicineRecruiting
Columbia University Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Whole-food, Plant-based Diet (WFPBD)

General Nutrition Counseling

Arm Description

Home-delivered WFPBD meals will be provided to participants, along with nutritional coaching and education. 12 meals a week will be delivered for the first 4 weeks, followed by 6 meals a week for the next 4 weeks. Finally, for the last 18 weeks they will not receive pre-packed meals, but will continue to receive WFPBD coaching. 30 participants are anticipated to be accrued in this arm.

Participants will receive general nutritional counseling weekly for the first 4 weeks, followed by monthly nutritional counseling for the following 18 weeks. 30 participants are anticipated to be accrued in this arm.

Outcomes

Primary Outcome Measures

Change in weight from baseline to 4 weeks post-randomization

All participates will be weighed at the baseline visit and at 4 weeks. A two-sample t-test will be used to compare the average change in weight (baseline weight minus 4-week weight).

Secondary Outcome Measures

Change in levels of serum hsCRP from baseline to 4, 8, and 26 weeks post-randomization

hsCRP is being measured as a marker of inflammation. All participants will have a blood draw at baseline, and 4, 8, and 26 week visits. Serum marker levels will be measured in a CLIA-approved laboratory. Graphical displays will be used to illustrate the change in values over time for continuous measures. There will be a line for each patient. A different color will be used for each treatment group. The average at each timepoint for each group will be computed. A two-way ANOVA will be used (or Kruskal-Wallis test if more appropriate) will be used to determine whether there are changes in the measures over time as well as between groups. The first analysis will be to determine whether there is a significant interaction between time and treatment. Subsequent analyses will depend on whether the interaction is statistically significant or not. Effect sizes will be summarized with point estimates and 95% confidence intervals.

Change in levels of serum IL-6 from baseline to 4, 8, and 26 weeks post-randomization

IL-6 is being measured as a marker of inflammation. All participants will have a blood draw at baseline, and 4, 8, and 26 week visits. Serum marker levels will be measured in a CLIA-approved laboratory. Graphical displays will be used to illustrate the change in values over time for continuous measures. There will be a line for each patient. A different color will be used for each treatment group. The average at each timepoint for each group will be computed. A two-way ANOVA will be used (or Kruskal-Wallis test if more appropriate) will be used to determine whether there are changes in the measures over time as well as between groups. The first analysis will be to determine whether there is a significant interaction between time and treatment. Subsequent analyses will depend on whether the interaction is statistically significant or not. Effect sizes will be summarized with point estimates and 95% confidence intervals.

Change in levels of serum glucose from baseline to 4, 8, and 26 weeks post-randomization

Glucose is being measured as a marker of insulin resistance. All participants will have a blood draw at baseline, and 4, 8, and 26 week visits. Serum marker levels will be measured in a CLIA-approved laboratory. Graphical displays will be used to illustrate the change in values over time for continuous measures. There will be a line for each patient. A different color will be used for each treatment group. The average at each timepoint for each group will be computed. A two-way ANOVA will be used (or Kruskal-Wallis test if more appropriate) will be used to determine whether there are changes in the measures over time as well as between groups. The first analysis will be to determine whether there is a significant interaction between time and treatment. Subsequent analyses will depend on whether the interaction is statistically significant or not. Effect sizes will be summarized with point estimates and 95% confidence intervals.

Change in levels of serum leptin from baseline to 4, 8, and 26 weeks post-randomization

Leptin is being measured as a marker of metabolism. All participants will have a blood draw at baseline, and 4, 8, and 26 week visits. Serum marker levels will be measured in a CLIA-approved laboratory. Graphical displays will be used to illustrate the change in values over time for continuous measures. There will be a line for each patient. A different color will be used for each treatment group. The average at each timepoint for each group will be computed. A two-way ANOVA will be used (or Kruskal-Wallis test if more appropriate) will be used to determine whether there are changes in the measures over time as well as between groups. The first analysis will be to determine whether there is a significant interaction between time and treatment. Subsequent analyses will depend on whether the interaction is statistically significant or not. Effect sizes will be summarized with point estimates and 95% confidence intervals.

Change in levels of serum adiponectin from baseline to 4, 8, and 26 weeks post-randomization

Adiponectin is being measured as a marker of metabolism. All participants will have a blood draw at baseline, and 4, 8, and 26 week visits. Serum marker levels will be measured in a CLIA-approved laboratory. Graphical displays will be used to illustrate the change in values over time for continuous measures. There will be a line for each patient. A different color will be used for each treatment group. The average at each timepoint for each group will be computed. A two-way ANOVA will be used (or Kruskal-Wallis test if more appropriate) will be used to determine whether there are changes in the measures over time as well as between groups. The first analysis will be to determine whether there is a significant interaction between time and treatment. Subsequent analyses will depend on whether the interaction is statistically significant or not. Effect sizes will be summarized with point estimates and 95% confidence intervals.

Change in levels of serum direct LDL from baseline to 4, 8, and 26 weeks post-randomization

Direct LDL is being measured as a marker of cardiovascular risk. All participants will have a blood draw at baseline, and 4, 8, and 26 week visits. Serum marker levels will be measured in a CLIA-approved laboratory. Graphical displays will be used to illustrate the change in values over time for continuous measures. There will be a line for each patient. A different color will be used for each treatment group. The average at each timepoint for each group will be computed. A two-way ANOVA will be used (or Kruskal-Wallis test if more appropriate) will be used to determine whether there are changes in the measures over time as well as between groups. The first analysis will be to determine whether there is a significant interaction between time and treatment. Subsequent analyses will depend on whether the interaction is statistically significant or not. Effect sizes will be summarized with point estimates and 95% confidence intervals.

Change in levels of HDL from baseline to 4, 8, and 26 weeks post-randomization

HDL is being measured as a marker of cardiovascular risk. All participants will have a blood draw at baseline, and 4, 8, and 26 week visits. Serum marker levels will be measured in a CLIA-approved laboratory. Graphical displays will be used to illustrate the change in values over time for continuous measures. There will be a line for each patient. A different color will be used for each treatment group. The average at each timepoint for each group will be computed. A two-way ANOVA will be used (or Kruskal-Wallis test if more appropriate) will be used to determine whether there are changes in the measures over time as well as between groups. The first analysis will be to determine whether there is a significant interaction between time and treatment. Subsequent analyses will depend on whether the interaction is statistically significant or not. Effect sizes will be summarized with point estimates and 95% confidence intervals.

Change in levels of fasting triglycerides from baseline to 4, 8, and 26 weeks post-randomization

Fasting triglycerides are being measured as a marker of cardiovascular risk. All participants will have a blood draw at baseline, and 4, 8, and 26 week visits. Serum marker levels will be measured in a CLIA-approved laboratory. Graphical displays will be used to illustrate the change in values over time for continuous measures. There will be a line for each patient. A different color will be used for each treatment group. The average at each timepoint for each group will be computed. A two-way ANOVA will be used (or Kruskal-Wallis test if more appropriate) will be used to determine whether there are changes in the measures over time as well as between groups. The first analysis will be to determine whether there is a significant interaction between time and treatment. Subsequent analyses will depend on whether the interaction is statistically significant or not. Effect sizes will be summarized with point estimates and 95% confidence intervals.

Change in levels of serum insulin from baseline to 4, 8, and 26 weeks post-randomization

Insulin is being measured as a marker of insulin resistance. All participants will have a blood draw at baseline, and 4, 8, and 26 week visits. Serum marker levels will be measured in a CLIA-approved laboratory. Graphical displays will be used to illustrate the change in values over time for continuous measures. There will be a line for each patient. A different color will be used for each treatment group. The average at each timepoint for each group will be computed. A two-way ANOVA will be used (or Kruskal-Wallis test if more appropriate) will be used to determine whether there are changes in the measures over time as well as between groups. The first analysis will be to determine whether there is a significant interaction between time and treatment. Subsequent analyses will depend on whether the interaction is statistically significant or not. Effect sizes will be summarized with point estimates and 95% confidence intervals.

Change in FACT-P score as an indicator of quality of life from baseline to 4, 8, and 26

The FACT-P is a self-administered questionnaire that asks patients with prostate cancer about well-being in different aspects of life. It provides different statements and patients record how much they agree or disagree on a Likert scale. FACT-P scores will be calculated based on the participant responses to the questionnaire given at baseline, 4 weeks, 8 weeks, and 26 weeks. Scores can range from 0 to 156 with higher scores indicating a higher quality of life. Mean scores for all participants in each arm will be calculated and compared using a two-way ANOVA.

Change in mean measures of body fat percentage, as determined by DEXA scan, from baseline to 4 and 26 weeks post-randomization

All participants will receive a DEXA scan at baseline, 4 weeks, and 26 weeks to determine body fat percentage. Average body fat percentage will be calculated for each study arm and compared using a two-way ANOVA.

Change in the diversity of the fecal microbiome from baseline to 4 and 26 weeks post-randomization

For the microbiome data obtained through 16S rRNA sequencing, DADA2 based approach will be used to generate the counts data for the amplicon sequence variants (ASVs). Taxonomy assignment will be based on commonly used reference databases. Alpha diversity such as the Shannon index will be calculated for each sample and summarized and evaluated similarly as other continuous endpoints. Between sample composition differences will be assessed based on beta diversity measures such as weighted/unweighted Unifrac and Bray-Curtis distances and evaluated using PERMANOVA type of approaches such as adonis. Differential abundance analysis will be carried out using DESeq2 or a non-parametric approach such as Wilcoxon signed rank test on the data with variance stabilizing transformation.

Change in mean fat free body mass, as determined by DEXA scan, from baseline to 4 and 26 weeks post-randomization.

All participants will receive a DEXA scan at baseline, 4 weeks, and 26 weeks to determine fat free body mass. Average fat free body mass will be calculated for each study arm and compared using a two-way ANOVA.

Change in mean body mass including fat, as determined by DEXA scan, from baseline to 4 and 26 weeks post-randomization.

All participants will receive a DEXA scan at baseline, 4 weeks, and 26 weeks to determine body mass including fat. Average body mass including fat will be calculated for each study arm and compared using a two-way ANOVA.

Change in levels of hemoglobin A1c from baseline to 4, 8, and 26 weeks post-randomization

Hemoglobin A1C is being measured as a marker of insulin resistance. All participants will have a blood draw at baseline, and 4, 8, and 26 week visits. Serum marker levels will be measured in a CLIA-approved laboratory. Graphical displays will be used to illustrate the change in values over time for continuous measures. There will be a line for each patient. A different color will be used for each treatment group. The average at each timepoint for each group will be computed. A two-way ANOVA will be used (or Kruskal-Wallis test if more appropriate) will be used to determine whether there are changes in the measures over time as well as between groups. The first analysis will be to determine whether there is a significant interaction between time and treatment. Subsequent analyses will depend on whether the interaction is statistically significant or not. Effect sizes will be summarized with point estimates and 95% confidence intervals.

Change in BMI from baseline to 4, 8, and 26 weeks post-randomization.

Height (in meters) and weight (in kilograms) will be measured at baseline, 4 weeks, 8 weeks, and 26 weeks. BMI (kg/m^2) will be derived from these measures. Average BMI will be calculated for each study arm and compared using a two-way ANOVA.

Full Information

NCT ID

NCT05471414

First Posted

July 19, 2022

Last Updated

July 24, 2023

Sponsor

Weill Medical College of Cornell University

Collaborators

Plantable Inc., Prostate Cancer Foundation

1. Study Identification

Unique Protocol Identification Number

NCT05471414

Brief Title

Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer

Acronym

WFPBD

Official Title

Whole-Food Plant-Based Diet (WFPBD) to Control Weight and Metabo-Inflammation in Overweight/Obese Men With Prostate Cancer Receiving Androgen Deprivation Therapy (ADT): A Multi-Center Randomized Control Trial

Study Type

Interventional

2. Study Status

Record Verification Date

July 2023

Overall Recruitment Status

Recruiting

Study Start Date

September 22, 2022 (Actual)

Primary Completion Date

February 2024 (Anticipated)

Study Completion Date

July 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Weill Medical College of Cornell University

Collaborators

Plantable Inc., Prostate Cancer Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The study is comparing the effect on weight of providing home-delivered whole-food, plant-based meals versus standard, general nutritional counseling to men with prostate cancer on androgen-deprivation therapy (ADT).

Detailed Description

Prostate cancer is the most common cancer diagnosis for men in the United States. For patients with advanced or recurrent disease, ADT has is the cornerstone of systemic treatment. Overall, almost half of prostate cancer patients will undergo ADT at some point during their treatment. Unfortunately, ADT has metabolic side effects, including weight gain, central adiposity, and insulin resistance. This study is a multi-site randomized phase II trial comparing a home-delivered whole food, plant-based diet (WFPBD) with specialized behavioral coaching to standard dietary intervention with general nutritional counseling to assess the efficacy of a WFPBD in promoting weight loss in overweight/obese men receiving ADT. The home-delivered WFPBD will be for 28 days with 12 meals a week followed by 28 days with 6 meals a week; followed by self-prepared WFPBD for 18 weeks (for a total of 26 weeks). The study hypothesis is that a WFPBD will decrease body weight and decrease systemic metabo-inflammation in overweight/obese men (BMI > 27) with prostate cancer receiving ADT. Secondary objectives will be to assess the effects of a WFPBD on adiposity, markers of inflammation (hsCRP, IL-6), metabolism (insulin, glucose, leptin, adiponectin), and fecal microbiota that may contribute to prostate cancer progression; to assess the effects of a WFPBD on quality of life; and to assess the durability of any observed effect (weight, adiposity, markers of inflammation and metabolism, fecal microbiota) of the intervention after cessation of the meal-delivery service.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Prostate Cancer

7. Study Design

Primary Purpose

Treatment

Study Phase

Not Applicable

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

Whole-food, Plant-based Diet (WFPBD)

Arm Type

Experimental

Arm Description

Arm Title

General Nutrition Counseling

Arm Type

Active Comparator

Arm Description

Intervention Type

Behavioral

Intervention Name(s)

Whole-food, Plant-Based Diet

Intervention Description

Pre-packaged, plant-based meals (prepared by Plantable) will be delivered weekly to participants' homes for 8 weeks. Meals are made with whole ingredients including whole grains, vegetables, legumes, nuts and seeds. Added sugar, animal-based products, refined grains, and processed foods are not used in any meal. Participants will be coached via phone calls, SMS, emails, and the app throughout the intervention to prepare meals in accordance with the diet. Participants will have access to a Registered Dietitian. During the first 4 weeks, 12 meals/week will be provided to participants; followed by 6 meals/week for the next 4 weeks; followed by 18 weeks where participants will continue to receive coaching, but will be expected to make all their own whole-food, plant-based meals using Plantable's assistance.

Intervention Type

Behavioral

Intervention Name(s)

General Nutritional Counseling

Intervention Description

All study participants will receive consult with a Registered Dietitian at the Baseline visit and visit 1 study assessments. After visit 1, study participants assigned to the general nutritional counseling arm will receive an additional in-person or telehealth consultation with a Registered Dietitian that will consist of identification and counseling to improve diet quality and achieve a healthy body weight consistent with American Cancer Society guidelines. Study participants in the control group will continue to receive general nutritional counseling and education with weekly scheduled telephone consultations with a Registered Dietitian for the first 4 weeks of the study period. For the remainder of the study period, they will receive counseling and education from Registered Dietitians via monthly scheduled phone calls.

Primary Outcome Measure Information:

Title

Change in weight from baseline to 4 weeks post-randomization

Description

All participates will be weighed at the baseline visit and at 4 weeks. A two-sample t-test will be used to compare the average change in weight (baseline weight minus 4-week weight).

Time Frame

Baseline; 4 weeks post-randomization

Secondary Outcome Measure Information:

Title

Change in levels of serum hsCRP from baseline to 4, 8, and 26 weeks post-randomization

Description

Time Frame

Baseline; 4, 8, and 26 weeks post-randomization

Title

Change in levels of serum IL-6 from baseline to 4, 8, and 26 weeks post-randomization

Description

Time Frame

Baseline; 4, 8, and 26 weeks post-randomization

Title

Change in levels of serum glucose from baseline to 4, 8, and 26 weeks post-randomization

Description

Time Frame

Baseline; 4, 8, and 26 weeks post-randomization

Title

Change in levels of serum leptin from baseline to 4, 8, and 26 weeks post-randomization

Description

Time Frame

Baseline; 4, 8, and 26 weeks post-randomization

Title

Change in levels of serum adiponectin from baseline to 4, 8, and 26 weeks post-randomization

Description

Time Frame

Baseline; 4, 8, and 26 weeks post-randomization

Title

Change in levels of serum direct LDL from baseline to 4, 8, and 26 weeks post-randomization

Description

Time Frame

Baseline; 4, 8, and 26 weeks post-randomization

Title

Change in levels of HDL from baseline to 4, 8, and 26 weeks post-randomization

Description

Time Frame

Baseline; 4, 8, and 26 weeks post-randomization

Title

Change in levels of fasting triglycerides from baseline to 4, 8, and 26 weeks post-randomization

Description

Time Frame

Baseline; 4, 8, and 26 weeks post-randomization

Title

Change in levels of serum insulin from baseline to 4, 8, and 26 weeks post-randomization

Description

Time Frame

Baseline; 4, 8, and 26 weeks post-randomization

Title

Change in FACT-P score as an indicator of quality of life from baseline to 4, 8, and 26

Description

Time Frame

Baseline; 4, 8, and 26 weeks post-randomization

Title

Change in mean measures of body fat percentage, as determined by DEXA scan, from baseline to 4 and 26 weeks post-randomization

Description

Time Frame

Baseline; 4 weeks and 26 weeks post-randomization

Title

Change in the diversity of the fecal microbiome from baseline to 4 and 26 weeks post-randomization

Description

Time Frame

Baseline; 4 weeks and 26 weeks post-randomization

Title

Change in mean fat free body mass, as determined by DEXA scan, from baseline to 4 and 26 weeks post-randomization.

Description

Time Frame

Baseline; 4 weeks and 26 weeks post-randomization

Title

Change in mean body mass including fat, as determined by DEXA scan, from baseline to 4 and 26 weeks post-randomization.

Description

Time Frame

Baseline; 4 weeks and 26 weeks post-randomization

Title

Change in levels of hemoglobin A1c from baseline to 4, 8, and 26 weeks post-randomization

Description

Time Frame

Baseline; 4, 8, and 26 weeks post-randomization

Title

Change in BMI from baseline to 4, 8, and 26 weeks post-randomization.

Description

Time Frame

Baseline; 4, 8, and 26 weeks post-randomization

10. Eligibility

Sex

Male

Gender Based

Yes

Gender Eligibility Description

Male subjects with a diagnosis of prostate cancer

Minimum Age & Unit of Time

45 Years

Maximum Age & Unit of Time

99 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria Histologically or cytologically confirmed adenocarcinoma of the prostate Receiving androgen deprivation therapy (ADT) with an LHRH/GnRH analogue (agonist/antagonist); or have undergone bilateral orchiectomy. Patients with localized prostate cancer, non-metastatic castrate resistant prostate cancer (CRPC), metastatic hormone sensitive prostate cancer and metastatic CRPC are all eligible. On ADT for at least 24 weeks pre-study with anticipation of at least 26 more weeks of therapy from the date of initiation of the dietary intervention Patients receiving an anti-androgen (including, but not limited to drugs such as bicalutamide, abiraterone, enzalutamide or apalutamide) are eligible if they have been on therapy for at least 3 months and plan to continue for the duration of the study At least 3 months post completion of chemotherapy and/or radiation Bone resorptive agents such as bisphosphanates and denosumab are allowed. Testosterone level <50 ng/dL Age ≥ 45 years BMI ≥ 27 ECOG performance status of 0 to 1 Adequate organ and marrow function, based upon meeting all of the following laboratory criteria: White blood cell count ≥ 2500/mm3 (≥ 2.5 GI/L) Platelets ≥ 100,000/mm3 (≥ 100 GI/L) without transfusion Hemoglobin ≥ 9 g/dL (≥ 90 g/L) Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin ≤ 2x ULN (or for subjects with Gilbert's disease direct bilirubin WNL) Serum albumin ≥ 2.8 g/dl Willingness and ability to comply with all study-related procedures Capable of understanding and complying with the protocol requirements and must have signed the informed consent document Exclusion Criteria Insulin-dependent diabetes mellitus Nut or legume allergy, gluten intolerance or celiac disease Currently consuming a vegetarian or vegan diet Concurrent participation in other nutrition or weight loss programs Expected changes in chronic medications, including statins or oral diabetes medication during the study period (including a change in medication dosage) Expected radiation, chemotherapy, bone resorptive agents or anti-androgen within 2 months of beginning the diet intervention Expected changes in exercise patterns during the study period Psychiatric illnesses or social situations that would limit compliance with study requirements, including a living situation that does not allow for the delivery of Plantable prepared meals, or the inability or lack of equipment to perform basic cooking tasks Known history of electrolyte imbalance or micronutrient deficiency, e.g., magnesium, cobalamin Ongoing use of warfarin anticoagulants Diagnosed, active inflammatory bowel disease Inability to receive Emails or have a smart phone

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

GUONC Research Team

Phone

212-746-1480

guonc@med.cornell.edu

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

David M Nanus, MD

Organizational Affiliation

Weill Medical College of Cornell University

Official's Role

Principal Investigator

Facility Information:

Facility Name

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

City

Baltimore

State/Province

Maryland

ZIP/Postal Code

21231

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Channing Paller, M.D.

Phone

202-660-6501

cpaller1@jhmi.edu

First Name & Middle Initial & Last Name & Degree

Channing Paller, MD

Facility Name

Weill Cornell Medicine

City

New York

State/Province

New York

ZIP/Postal Code

10021

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

David Nanus, M.D.

Phone

646-962-2072

dnanus@med.cornell.edu

First Name & Middle Initial & Last Name & Degree

Sarah Yuan

say7001@med.cornell.edu

First Name & Middle Initial & Last Name & Degree

David Nanus, M.D.

Facility Name

Columbia University Medical Center

City

New York

State/Province

New York

ZIP/Postal Code

10032

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Mark Stein

Phone

212-305-5874

mns2146@cumc.columbia.edu

First Name & Middle Initial & Last Name & Degree

Mark Stein, MD

12. IPD Sharing Statement

Plan to Share IPD

Learn more about this trial

Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer

We'll reach out to this number within 24 hrs